Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Diabetes Care Devices
Return to: MDBR Home | Specialty Devices | Diabetes Care Devices

Ascensia Diabetes Care, Insulet partner to connect Contour Next One and Omnipod

Published 09 June 2017

Ascensia Diabetes Care announced it has entered into a strategic alliance by signing a development agreement with Insulet, the leader in tubeless insulin pump technology with its Omnipod Insulin Management System (the Omnipod System).

Under the terms of this agreement, the Ascensia CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) will connect to Insulet's next-generation Omnipod System (the Omnipod Dash™ System), which is currently in development.

Seamlessly connecting the CONTOUR®NEXT ONE BGMS and the Omnipod Dash™ System will provide people living with diabetes with an innovative continuous insulin delivery system to manage their diabetes, powered by remarkably accurate blood glucose readings.

The CONTOUR®NEXT ONE BGMS will pair, via Bluetooth Low Energy (BLE), with the Omnipod Dash™ Personal Diabetes Manager (Omnipod Dash™ PDM) to automatically transmit a person's blood glucose readings directly into the system.

 These readings will be used by the Omnipod Dash™ PDM to calculate insulin dosing and support highly accurate delivery of insulin for people living with diabetes.

Under the terms of this worldwide non-exclusive agreement, Insulet will develop and seek marketing clearance for the Omnipod Dash™ PDM, with collaboration from Ascensia Diabetes Care who will provide the CONTOUR®NEXT ONE meter and CONTOUR®NEXT test strips.

"We are delighted to enter into this agreement that brings together these innovative technologies from both companies," said Michael Kloss, CEO, Ascensia Diabetes Care.

"The integration of our BGM system with Insulet's tubeless insulin pump system has significant potential to help people take control of their lives and their diabetes. We are pleased that our highly accurate system has been chosen to provide the critical blood glucose data that will be used by the Omnipod Dash™ PDM to calculate insulin dosing for patients."

"We are thrilled to partner with Ascensia as part of our development efforts on our next-generation Omnipod Dash™ platform, which will allow Insulet to maintain its competitive edge with truly innovative and differentiated products," said Shacey Petrovic, President and Chief Operating Officer.

The CONTOUR®NEXT ONE BGMS received 510(k) clearance from the FDA in November 2016 and has been shown to meet the stricter accuracy requirements of the FDA Over-the-Counter BGMS Guidance that was recently issued in 2016.

In a clinical study, 95% of blood glucose results obtained with the CONTOUR®NEXT ONE BGMS were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests.1

Michael added, "This alliance is the next step in our goal of providing integrated solutions for people living with diabetes. We believe that integrated diabetes management is the future and are happy to work with partners that will help us to achieve this goal together.

“One aspect of this is pump therapy, where we have established ourselves as the partner of choice for blood glucose monitoring in the pump sector. We are excited that Insulet recognizes the value the CONTOUR®NEXT ONE BGMS can bring to users of Omnipod's product platform."



Source: Company Press Release